Baidu
map

JACC:PCI术后心肌梗死面积可预测死亡和心衰风险

2016-04-05 崔倩 译 MedSci原创

ST段抬高心肌梗死(STEMI)患者再灌注可减少梗死面积和提高生存率。然而,在当代梗死面积和预后的直观联系一直没有令人信服地被证明。本研究旨在确定在STEMI患者中早期经皮冠状动脉介入治疗(PCI)评估梗死面积和随后的心脏衰竭全因死亡率,再梗死,住院之间的关系的强度。研究人员从10个随机急诊PCI试验(共2632例患者)进行了汇集患者水平分析,其梗死面积在随机分配后1个月内通过心脏磁共振(CMR)

ST段抬高型心肌梗死(STEMI)患者再灌注可减少梗死面积和提高生存率。然而,梗死面积和预后的直观联系一直没有令人信服地被证明。

本研究旨在确定在STEMI患者中早期经皮冠状动脉介入治疗(PCI)评估梗死面积和随后的心脏衰竭全因死亡率,再梗死,住院之间的关系的强度。

研究人员从10个随机急诊PCI试验(共2632例患者)进行了汇集患者水平分析,其梗死面积在随机分配后1个月内通过心脏磁共振(CMR)成像或99锝m-甲氧基异丁基异腈单光子发射型计算机断层扫描进行评估,临床随访≥6个月。

1889例患者梗死面积通过CMR(71.8%)评估,743例患者(28.2%)通过SPECT评估。到梗死面积测量的平均天数为STEMI后4天(3,10天)(第25,第75百分位)。平均梗死面积(%左心室心肌质量)为17.9%(8.0%,29.8%),临床随访平均时间为352天(185,371天)。Kaplan-Meier法评估1年全因死亡率,再梗死和HF住院率分别为2.2%,2.5%和2.6%。心肌梗死面积(每增加5%)和随后的死亡率(Cox-调整的风险比:1.19 [95%置信区间:1.18〜1.20]; P<0.0001)和心脏衰竭住院(调整后的危险比:1.20 [95%置信区间:1.19至1.21]; p<0.0001)之间有显著关联,独立于年龄、性别、糖尿病、高血压、高脂血症、当前吸烟、左前降支与非–左前降支梗塞血管、有症状到第一次使用设备和基线TIMI(心肌梗死溶栓)流0/1 vs 2/3。梗死面积与后续再梗死没有显著联系。

心肌梗死面积,PCI术后1个月内通过CMR或99锝m-甲氧基异丁基异腈SPECT测量,在1年内与全因死亡率和心力衰竭住院显著相关。因此,心肌梗死面积可作为临床试验的一个很重要的终点,对于护理STEMI患者是一个很重要的预后指标。

原始出处:

Gregg W. Stone,Harry P. Selker,Holger Thiele,et al.Relationship Between Infarct Size and Outcomes Following Primary PCI,JACC,2016.4.5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853509, encodeId=f658185350914, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 13 00:47:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633821, encodeId=b7c01633821fb, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Mar 17 10:47:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325220, encodeId=b2121325220c1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389440, encodeId=32051389440ce, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486418, encodeId=42f8148641805, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76030, encodeId=416de603063, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:37:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75930, encodeId=4bd8e593057, content=介入治疗的应用,需要临床进一步观察。, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Wed Apr 06 12:47:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2017-01-13 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853509, encodeId=f658185350914, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 13 00:47:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633821, encodeId=b7c01633821fb, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Mar 17 10:47:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325220, encodeId=b2121325220c1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389440, encodeId=32051389440ce, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486418, encodeId=42f8148641805, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76030, encodeId=416de603063, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:37:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75930, encodeId=4bd8e593057, content=介入治疗的应用,需要临床进一步观察。, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Wed Apr 06 12:47:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2017-03-17 zxl736
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853509, encodeId=f658185350914, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 13 00:47:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633821, encodeId=b7c01633821fb, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Mar 17 10:47:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325220, encodeId=b2121325220c1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389440, encodeId=32051389440ce, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486418, encodeId=42f8148641805, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76030, encodeId=416de603063, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:37:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75930, encodeId=4bd8e593057, content=介入治疗的应用,需要临床进一步观察。, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Wed Apr 06 12:47:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853509, encodeId=f658185350914, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 13 00:47:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633821, encodeId=b7c01633821fb, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Mar 17 10:47:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325220, encodeId=b2121325220c1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389440, encodeId=32051389440ce, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486418, encodeId=42f8148641805, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76030, encodeId=416de603063, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:37:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75930, encodeId=4bd8e593057, content=介入治疗的应用,需要临床进一步观察。, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Wed Apr 06 12:47:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853509, encodeId=f658185350914, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 13 00:47:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633821, encodeId=b7c01633821fb, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Mar 17 10:47:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325220, encodeId=b2121325220c1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389440, encodeId=32051389440ce, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486418, encodeId=42f8148641805, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76030, encodeId=416de603063, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:37:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75930, encodeId=4bd8e593057, content=介入治疗的应用,需要临床进一步观察。, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Wed Apr 06 12:47:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853509, encodeId=f658185350914, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 13 00:47:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633821, encodeId=b7c01633821fb, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Mar 17 10:47:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325220, encodeId=b2121325220c1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389440, encodeId=32051389440ce, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486418, encodeId=42f8148641805, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76030, encodeId=416de603063, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:37:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75930, encodeId=4bd8e593057, content=介入治疗的应用,需要临床进一步观察。, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Wed Apr 06 12:47:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-06 dhzzm

    学习了,很好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1853509, encodeId=f658185350914, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 13 00:47:00 CST 2017, time=2017-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633821, encodeId=b7c01633821fb, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Fri Mar 17 10:47:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325220, encodeId=b2121325220c1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389440, encodeId=32051389440ce, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486418, encodeId=42f8148641805, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Apr 07 12:47:00 CST 2016, time=2016-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76030, encodeId=416de603063, content=学习了,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Wed Apr 06 15:37:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=75930, encodeId=4bd8e593057, content=介入治疗的应用,需要临床进一步观察。, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Wed Apr 06 12:47:00 CST 2016, time=2016-04-06, status=1, ipAttribution=)]
    2016-04-06 Lisa971

    介入治疗的应用,需要临床进一步观察。

    0

相关资讯

ACC 2016:α硫辛酸不能降低PCI中对比剂的肾损伤发生率(CARIN)

美国心脏病学年会上称,一种新型改良的α硫辛酸不能有效的防止PCI中对比剂诱导的肾脏损伤。布莱根妇女医院心血管介入项目的执行董事Bhatt博士说:“糖尿病或肾病患者进行PCI时,对比剂诱导的肾损伤是常见的问题,现有的有效疗法是预水化。当前有很多尝试降低造影剂对肾脏损害的工作,但是目前造影前水化仍是最佳方案,当前我们迫切的需要新的治疗方法。”CARIN试验中,Bhatt和同事评估看一种新型α-硫辛酸的

JACC子刊:新一代药物洗脱支架PCI后,女性更容易出现胸痛!

合并分析DUTCH PEERS和TWENTE随机试验后发现,使用新一代药物洗脱支架进行PCI的临床相关性胸痛的发生率具有性别差异,女性显著高于男性!合并分析研究共包括3202名稳定性或急性ACS患者,使用新一代永久性聚合物涂层的药物洗脱支架治疗。DUTCH PEERS试验中,患者随机分为Resolute佐他莫司洗脱支架 (Medtronic Vascular)或Xience V依维莫司洗脱支架(A

JAMA Intern Med:我国PCI数量激增,但诊疗规范性不足(CathPCI研究)

         由国家卫生计生委“2012-2014年度卫生公益性行业科研专项”支持、中国医学科学院阜外医院牵头组织实施的“冠心病医疗结果评价和临床转化研究(ChinaPEACE)”中的回顾性冠脉造影和介入治疗(CathPCI)研究主要结果显示,2001-2011年间我国冠脉造影和经皮冠状动脉介入治疗(PCI)量迅猛增长,手术技术显著进步,

JACC:经导管主动脉瓣置换术加左冠状动脉主干PCI安全可行

左冠状动脉主干(LM)经导管主动脉瓣置换术(TAVR)和经皮冠状动脉介入治疗(PCI)的方法经常用于主动脉瓣狭窄和LM疾病共存的高风险患者。TAVR加LM的PCI的结果还没有被报道。TAVR-LM登记的主要目的是评估接受TAVR加LP PCI患者的临床结果。研究人员回顾性收集了204例接受TAVR加LM PCI患者的临床,超声心动图,计算机断层扫描,特点及预后。总体而言,在预先存在LM支架接受TA

JACC:与PCI相比,CABG能够更大幅度的降低心梗有关的死亡率

在随机试验在,比较冠状动脉旁路移植术(CABG)和经皮冠状动脉介入治疗(PCI)的具体死因没有可用数据。

JAMA Surg:为何接受冠脉支架介入术与患者预后明显相关?

背景目前医生主要依据患者疾病原因推迟冠状动脉支架置入术。然而,防止支架的原因或许是导致民众出现术后主要不良心血管事件(MACE)的一个重要的风险因素。 目的该研究的目的是确定冠状动脉支架放置术指征是否为导致民众出现MACE的主要危险因素。 设计该研究为回顾性队列研究,参与人员均于2000.1.1-2010.12.31在美国退伍军人医院接受冠状动脉支架置入术,并在2年内接受非心脏手术。研究人员使用逻

Baidu
map
Baidu
map
Baidu
map